期刊文献+

多巴丝肼片联合普拉克索治疗帕金森病患者的临床效果分析 被引量:13

Clinical effect of dobutamine tablets combined with praxol in the treatment of Parkinson’s disease
下载PDF
导出
摘要 目的探究多巴丝肼片联合普拉克索治疗帕金森病的临床效果。方法选择浙江省天台县人民医院2018年1月—2019年1月收治的36例帕金森病患者作为研究对象,采用随机数字表法分成对照组和研究组,每组18例,对照组采用多巴丝肼片治疗,研究组采用多巴丝肼片联合普拉克索治疗。比较两组患者治疗前后帕金森综合征统一评分量表(UPDRS)、蒙特利尔认知评估量表(Mo CA)评分,以及治疗总有效率及治疗期间不良反应发生率。结果治疗前,两组患者UPDRS、Mo CA评分比较,差异无统计学意义(P>0.05);治疗后,研究组患者UPDRS评分低于对照组,Mo CA评分高于对照组(P<0.05)。研究组患者治疗期间的不良反应发生率(5.6%)低于对照组(16.7%)(P<0.05)。研究组患者治疗总有效率(94.4%)高于对照组(77.8%)(P<0.05)。结论帕金森病患者采用多巴丝肼片联合普拉克索治疗,不仅能有效改善患者的临床症状,还能有效提高其认知功能,且患者治疗期间的不良反应发生率较低。 Objective To explore the clinical effects of dobutamine tablets combined with praxol in the treatment of Parkinson’s disease(PD).Methods From January 2018 to January 2019,36 patients with Parkinson’s disease in Tiantai People’s Hospital were randomly divided into two groups:control group(n=18)and study group(n=18),the control group(n=18)was treated with dopamine tablets,and the patients in control group were divided into two groups,patients in the study group were treated with dopamine tablets combined with praxol.The Unified Parkinson’s syndrome Rating Scale(UPDRS),Montreal Cognitive Assessment Scale(MoCA)scores before and after treatment,the total effective rate of treatment and the incidence of adverse reactions during treatment were compared between the two groups.Results Before treatment,there was no significant difference in UPDRS and MOCA scores between the two groups(P>0.05).After treatment,the UPDRS score of the study group was lower than that of the control group,and the MOCA score was higher than that of the control group(P<0.05).The incidence of adverse reactions in the study group(5.6%)was lower than that in the control group(16.7%)(P<0.05).The total effective rate of the study group(94.4%)was higher than that of the control group(77.8%)(P<0.05).Conclusion The patients with Parkinson’s disease treated with doxycycline combined with pramipexole can not only effectively improve the clinical symptoms,but also effectively improve their cognitive function,and the incidence of adverse reactions during the treatment is low.
作者 许佳颖 侯群
出处 《中国全科医学》 CAS 北大核心 2019年第S02期35-37,共3页 Chinese General Practice
关键词 帕金森病 多巴丝肼片 普拉克索 治疗结果 Parkinson disease Dopamine tablets Praxol Treatment outcome
  • 相关文献

参考文献15

二级参考文献149

  • 1裘涛,陈眉,陶水良,代建峰,吴乐程,张宾辉.乌灵菌粉对脑卒中后抑郁大鼠海马区单胺类神经递质及行为学改变的影响[J].中国新药杂志,2007,16(11):857-860. 被引量:18
  • 2中华医学会神经病学分会帕金森病及运动障碍学组.帕金森病的诊断[J].中华神经科杂志,2006,.
  • 3Cummings JL. Intellectual impairment in Parkinson' s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol, 1988,1:24-36.
  • 4Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson' s disease. Mov Disord, 2005, 20: 1255-1263.
  • 5de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol, 2005, 62:1265-1269.
  • 6Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol, 2003, 60:387-392.
  • 7Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology, 2000, 55: 539 -544.
  • 8Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson' s disease: clinical and prognostic implications. Neurology, 1985, 35:522-526.
  • 9Burn DJ, Rowan EN, Minnett T, et al. Extrapyramidal features in Parkinson' s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord, 2003, 18:884-889.
  • 10Janvin CC, Larsen JP, Salmon DP, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord, 2006, 21: 337-342.

共引文献222

同被引文献131

引证文献13

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部